Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. At the time of writing this protocol it was not known whether radiation therapy was more effective than temozolomide in treating gliomas. The purpose if this randomized phase III trial was to study radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas.

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research, CCTG, MRC-NCRI, Brain Tumour Group

Closing Date of Accrual

March 2010

Trial Chairperson

Dr Claire Phillips, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

World Radiotherapy Awareness Day promotion at ESTRO26
10 June, 2026

Global cancer community prepares to unite for 2026 World Radiotherapy Awareness Day

LATEST NEWS: 10 June 2026 The global radiation therapy

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research